Statement on Medicare Proposal to Limit Aduhelm Coverage
ACHP’s responds to Medicare’s proposal to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm.
ACHP’s responds to Medicare’s proposal to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm.
Following new COVID testing guidance, ACHP comments on the lack of a coordinated national testing strategy and at-home test availability.
Following a White House announcement, ACHP responds to the lack of a coordinated national testing strategy and rapid at-home COVID test availability.
HealthLeaders recognizes ACHP and its members for innovation and recommendations on telehealth, drug pricing, health equity, access and more.
ACHP offers five recommendations to the Biden Administration regarding how to address at-home COVID-19 testing coverage.
